Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at Stifel Nicolaus

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reiterated by equities research analysts at Stifel Nicolaus in a report issued on Friday, March 29th, AnalystRatings.com reports. They presently have a $112.00 target price on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price would suggest a potential upside of 169.23% from the company’s previous close.

ESPR has been the topic of a number of other research reports. Zacks Investment Research lowered shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, February 8th. BidaskClub upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, January 31st. Chardan Capital reiterated a “hold” rating and issued a $50.00 price objective on shares of Esperion Therapeutics in a research note on Thursday, March 14th. ValuEngine lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. Finally, Cowen reiterated a “buy” rating and issued a $94.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday, January 15th. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Esperion Therapeutics has a consensus rating of “Hold” and a consensus target price of $73.69.

Esperion Therapeutics stock traded up $0.33 during mid-day trading on Friday, reaching $41.60. 476,471 shares of the company traded hands, compared to its average volume of 590,667. Esperion Therapeutics has a fifty-two week low of $33.06 and a fifty-two week high of $77.99. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -5.52 and a beta of 2.13.

In related news, major shareholder Target N. V. Biotech acquired 50,000 shares of the firm’s stock in a transaction on Thursday, March 14th. The shares were acquired at an average cost of $49.89 per share, with a total value of $2,494,500.00. Following the completion of the acquisition, the insider now directly owns 3,522,964 shares in the company, valued at approximately $175,760,673.96. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Roger S. Newton sold 25,000 shares of the stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $50.06, for a total transaction of $1,251,500.00. Following the transaction, the director now directly owns 548,726 shares in the company, valued at $27,469,223.56. The disclosure for this sale can be found here. Over the last ninety days, insiders have acquired 65,000 shares of company stock worth $3,155,550 and have sold 48,329 shares worth $2,280,206. Company insiders own 14.50% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. raised its position in shares of Esperion Therapeutics by 598.3% in the third quarter. Russell Investments Group Ltd. now owns 12,422 shares of the biopharmaceutical company’s stock valued at $551,000 after buying an additional 10,643 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Esperion Therapeutics by 3.4% in the third quarter. JPMorgan Chase & Co. now owns 71,095 shares of the biopharmaceutical company’s stock valued at $3,155,000 after buying an additional 2,348 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Esperion Therapeutics by 5.6% in the third quarter. Bank of New York Mellon Corp now owns 117,796 shares of the biopharmaceutical company’s stock valued at $5,227,000 after buying an additional 6,212 shares during the last quarter. BlackRock Inc. raised its position in shares of Esperion Therapeutics by 4.1% in the third quarter. BlackRock Inc. now owns 1,878,905 shares of the biopharmaceutical company’s stock valued at $83,367,000 after buying an additional 73,673 shares during the last quarter. Finally, Trexquant Investment LP acquired a new stake in shares of Esperion Therapeutics in the third quarter valued at about $848,000. 99.84% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Featured Article: Commodities

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.